

---

## Product Data Sheet

---

Product Name: RIDR-PI-103

Cat. No.: GC67903

### Chemical Properties

Cas. No. 2581114-71-6

Formula  $C_{27}H_{25}N_7O_4$  M.Wt 511.53

Solubility Storage 4°C, away from moisture and light

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure

### Background

RIDR-PI-103 is a reactive oxygen species (ROS)-induced drug release prodrug with a self-cyclizing moiety linked to a pan-PI3K inhibitor (PI-103). Doxorubicin and RIDR-PI-103 shows a synergistic effect in MDA-MB-361 and MDA-MB-231 cells to inhibit cancer cell proliferation<sup>[1][2]</sup>.

[1]. Mishra R, et al. Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth. *Int J Mol Sci.* 2021;22(4):2088

[2]. Rosalin Mishra, et al. Efficacy of RIDRPI103, a reactive oxygen species (ROS) activated prodrug in treatment of breast cancer [abstract]. In: *Proceedings of the 2019 San Antonio Breast Cancer Symposium*; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA):

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA